Reply to Anthony et al., “Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment”
Fofana M, Dowdy D. Reply to Anthony et al., “Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment”. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00427-17. PMID: 28539499, PMCID: PMC5444152, DOI: 10.1128/aac.00427-17.Commentaries, Editorials and Letters